Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril ...
Weight-loss drugs such as semaglutide are effective at tackling the biological drivers of Alzheimer’s disease, a new study ...
Researchers hoped results from the latest trial on low-dose lithium would settle the question of lithium’s potential to ...
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with ...
Families with rare gene mutations that cause Alzheimer's in middle age are giving scientists a unique window on the disease, ...
Researchers at Kindai University found that the amino acid L-arginine, costing about $2 a month, reduced amyloid-beta plaques in both fruit fly and mouse Alzheimer’s models. The orally administered ...
Families with rare gene mutations that cause Alzheimer's in middle age are giving scientists a unique window on the disease, ...
Morning Overview on MSN
A $2 amino acid supplement slashed Alzheimer’s brain plaque in every animal model scientists tested
A team at Kindai University in Osaka, Japan, fed ordinary L-arginine to fruit flies and mice engineered to develop ...
A new study suggests arginine may reduce Alzheimer’s-related protein buildup and inflammation, reshaping future treatment ...
Patients offered a new generation of Alzheimer’s drugs face a sharper debate over whether modest biological gains justify the risks of brain swelling, bleeding and intensive monitoring, after a large ...
For decades, Alzheimer’s disease has been seen as a brain disorder caused by toxic protein buildup, but new research suggests ...
Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results